Eidelman Virant Capital reduced its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 23.1% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 40,000 shares of the biotechnology company’s stock after selling 12,000 shares during the period. Eidelman Virant Capital’s holdings in Corcept Therapeutics were worth $722,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the business. Suntrust Banks Inc. grew its position in Corcept Therapeutics by 4.0% during the 2nd quarter. Suntrust Banks Inc. now owns 12,308 shares of the biotechnology company’s stock worth $145,000 after purchasing an additional 471 shares during the last quarter. Strs Ohio grew its position in Corcept Therapeutics by 2.0% during the 2nd quarter. Strs Ohio now owns 72,900 shares of the biotechnology company’s stock worth $860,000 after purchasing an additional 1,400 shares during the last quarter. TIAA CREF Investment Management LLC grew its position in Corcept Therapeutics by 0.7% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 347,171 shares of the biotechnology company’s stock worth $4,097,000 after purchasing an additional 2,360 shares during the last quarter. Metropolitan Life Insurance Co. NY grew its position in Corcept Therapeutics by 5.6% during the 1st quarter. Metropolitan Life Insurance Co. NY now owns 56,303 shares of the biotechnology company’s stock worth $617,000 after purchasing an additional 2,992 shares during the last quarter. Finally, American International Group Inc. grew its position in Corcept Therapeutics by 7.1% during the 1st quarter. American International Group Inc. now owns 46,000 shares of the biotechnology company’s stock worth $504,000 after purchasing an additional 3,042 shares during the last quarter. 62.22% of the stock is currently owned by institutional investors.

Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) traded down 2.95% during mid-day trading on Wednesday, hitting $19.11. 430,262 shares of the stock traded hands. The stock has a market cap of $2.17 billion, a P/E ratio of 95.07 and a beta of 2.12. The firm’s 50 day moving average price is $18.81 and its 200-day moving average price is $14.02. Corcept Therapeutics Incorporated has a 12-month low of $6.68 and a 12-month high of $20.77.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings results on Tuesday, August 1st. The biotechnology company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.08 by $0.02. The business had revenue of $35.56 million during the quarter, compared to analyst estimates of $31.37 million. Corcept Therapeutics had a net margin of 22.28% and a return on equity of 51.45%. The company’s quarterly revenue was up 80.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.01 earnings per share. Analysts predict that Corcept Therapeutics Incorporated will post $0.43 earnings per share for the current year.

WARNING: This report was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://theolympiareport.com/2017/11/01/eidelman-virant-capital-lowers-holdings-in-corcept-therapeutics-incorporated-cort.html.

Several brokerages have issued reports on CORT. BidaskClub raised shares of Corcept Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 18th. Stifel Nicolaus began coverage on shares of Corcept Therapeutics in a research report on Thursday, August 31st. They set a “buy” rating and a $20.00 price objective on the stock. Zacks Investment Research downgraded shares of Corcept Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, July 4th. Piper Jaffray Companies set a $18.00 price objective on shares of Corcept Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 24th. Finally, Ladenburg Thalmann Financial Services set a $20.00 price objective on shares of Corcept Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, July 18th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $17.17.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Institutional Ownership by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.